Dr. Suvannasankha is a graduate of Chulalongkorn University in Thailand. She completed her residency at Albert Einstein Medical Center in Philadelphia and a fellowship at Roswell Park Comprehensive Cancer Center in Buffalo, New York. She joined the Indiana University School of Medicine in 2003 and currently serves as an associate professor at the IU School of Medicine and researcher at the IU Simon Comprehensive Cancer Center. Dr. Suvannasankha’s research interests are in the molecular mechanism of drug resistance in hematologic malignancy and precision medicine. Her clinical expertise includes hematology-oncology and bone marrow transplant.

Ravi Vij, MD, MBA, is Professor of Medicine at the Washington University School of Medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia. Dr. Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He has research interests in multiple myeloma and AML/myelodysplastic syndromes. Dr. Vij serves on numerous committees including the International Myeloma Working Group (IWMG), the Core Transplant Myeloma and Leukemia Committees of the CALGB, the Steering Committee of the Multiple Myeloma Research Consortium, and the Myeloma Committee of the BMT Clinical Trials Network (CTN). His honors include the Multiple Myeloma Research Foundation Innovator Award (2013) and the Multiple Myeloma Research Consortium Center of Excellence Award (2011). He has authored more than 130 publications in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation. He has authored the book Contemporary Management of Multiple Myeloma and several chapters in books, including Multiple Myeloma and Plasma Cell Dyscrasias in the Washington Manual of Oncology. He has served as a review for journals including Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Experimental Hematology and Haematologica.

Craig Emmitt Cole, M.D. is a board-certified Hematologist who received his Bachelor of Science degree in physiology at Michigan State University and the College of Lyman Briggs, in East Lansing Michigan. Dr. Cole went on to receive his doctoral degree at the Ohio State University College of Medicine in Columbus, Ohio. He completed his Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan Health System, Ann Arbor, Michigan. Dr. Cole subsequently had a post-fellowship laboratory research position at the Jerome Lipper Multiple Myeloma Center of Medicine at Dana-Farber Cancer Institute in Boston, Massachusetts. This opportunity then led to him becoming an attending hematologist at Gundersen Health System in La Crosse, Wisconsin for 9 years. There he was an instructor for both the medical and nursing schools of the western campus of the University of Wisconsin School of Medicine and Public Health. He also served as Affiliate Faculty Member of Graduate Community Health Programs and Assistant Professor (Adjunct) at the University of Wisconsin-La Crosse, Department of Health Professions. While in Wisconsin, his clinical research interest was in multiple myeloma, malignant hematology, clinical apheresis, and patient reported outcomes in hematology. He then returned to the University of Michigan Rogel Cancer Center in Ann Arbor, Michigan as an Assistant Professor in the Division of Hematology/Oncology with his primary clinical and research interest being in multiple myeloma. In May of 2019, he returned to Michigan State University College of Human Medicine at Breslin Cancer Center as the Director of Clinical Research in Hematology/ Oncology and Multiple Myeloma. Dr. Cole has been participated in over 50 clinical trials in Multiple Myeloma and Malignant Hematology. He is a member of the International Myeloma Working Group, International Myeloma Society and the American Society of Hematology; he has published in national journals and presented at the American Society of Hematology International Myeloma Workshop, and the American Society for Apheresis meetings. He has lectured across the United States to patients, researchers and clinical providers in multiple myeloma, plasma cell dyscrasias, and disparities in cancer care. He has won awards for his work in student and resident teaching, multiple myeloma research, and patient advocacy. Dr. Cole has always had a strong commitment to equity of cancer care, patient empowerment, and community education by working with several local and national patient advocacy associations to bring the good news of myeloma research to everyone.

Natalie Callander, MD joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander graduated from Tufts University School of Medicine in Boston, MA, has completed residency at Bellevue Hospital in New York, as well as a Hematology/Oncology fellowship at the University of California-San Diego. Her board certifications include hematology, internal medicine, and medical oncology.

Kelvin Lee, MD, is Director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. Additional roles at IU include being Associate Dean for Cancer Research, professor in oncology, hematology/oncology, micro-biology and immunology and he currently serves as Interim Chair of the Division of Hematology/Oncology in the Depart medicine. Dr. Lee is a pioneering expert in CAR T cell research and application in the clinic. His work has identified sites to target and bind CAR T cells to malignant cells, defined how myeloma cells survive, and how cells communicate with each other to be more-or-less effective. Before leading the Simon Cancer Center, Dr. Lee became also became a leading expert in cancer disparities at Roswell Park Comprehensive Cancer Center in Buffalo, New York, where he served in roles ranging from Vice Chair of Medicine to Senior Vice President of Roswell Park’s Basic Sciences division. He also spent time at the University of Miami, Florida and started his career in various federal military-based medical research institutions. He served his medical fellowship in oncology at the University of Michigan in Ann Arbor, a residency at the University of Colorado Medical Center in Denver and earned his medical degree at Ann Arbor.